News

Otsuka, in accordance with the MOU, has engaged in a wide range of capital expenditures for the manufacture of pharmaceutical products, including investment in research and development of

Discovered by Takeda, TAK-438 belongs to a new class of inhibitors called potassium-competitive acid blockers (P-CABs) that show strong and sustainable acid secretion inhibitory effects as well as

Building upon over a decade of experience as the leading gene synthesis supplier in the US, GenScript has developed a new breakthrough technology: GenPlus Next-Generation Gene Synthesis. GenPlus

The placebo-controlled trial is designed to evaluate the safety and efficacy of OIT and CPNA as a prescribed treatment for patients with peanut allergy to follow under the

The option agreement with GW adds potential proprietary protection to the company’s pipeline, which includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.

Invasive mucormycosis is a life-threatening invasive fungal infection caused by certain emerging molds. The designation provides priority review and a five-year extension of market exclusivity in the US.

Under the deal, Salix has secured worldwide exclusive rights to RedHill’s RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. In return, Salix paid RedHill

Subject to the IND becoming effective, Ignyta plans to initiate a multicenter Phase I/II clinical study of RXDX-101 to be called Study Targeting ALK, ROS1 or TRKA/B/C (STARTRK-1).

Approximately 146 patients have been enrolled in the Phase III study to date. Over the past three months, patient screening by participating hospitals and patient enrollment have steadily